行情

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

实时行情|Nasdaq Last Sale

3.810
+0.070
+1.87%
已收盘, 16:00 12/09 EST
开盘
3.730
昨收
3.740
最高
3.840
最低
3.690
成交量
11.21万
成交额
--
52周最高
5.70
52周最低
3.200
市值
7,698.97万
市盈率(TTM)
-4.9257
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ANIX 新闻

  • Key events next week - healthcare
  • Seeking Alpha - Article.3天前
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.6天前
  • 美农场破产量飙升24%创6年新高 农业危机“在路上”?
  • 第一财经.6天前
  • 资金流向复盘 | 南下资金今日净流入港股超28亿港元
  • 华盛通.6天前

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

ANIX 简况

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.
展开

Webull提供Anixa Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。